Contraceptive methods and breast cancer risk: an update

Contracept Rep. 2000 Jul;11(2):9-11.


PIP: This paper presents updates on the issue of contraceptive methods and breast cancer. It is noted that over the years there have been misconceptions about the relationship between breast cancer and hormonal contraception. However, evidence suggests that oral and injectable contraceptives do not affect a woman's lifetime risk of breast cancer. According to the study by the Collaborative Group on Hormonal Factors in Breast Cancer on oral contraceptives (OCs) and breast cancer, the lack of an association among duration of use, dose, and breast cancer risk supports the hypothesis that OCs do not affect the disease. It has been found that 10 or more years after stopping use of the method, an OC user's relative risk of breast cancer is identical to that of a woman who has never used OCs. In the context of injectable contraceptives, pooled data from large case-control studies suggest no elevation in breast cancer risk in ever-users of depot-medroxyprogesterone acetate (DMPA). Although risk estimates are higher in certain subgroups, including short-term users and current users under 35 years, such effects are likely related to enhanced detection or accelerated growth of existing tumors.

MeSH terms

  • Biology
  • Breast Neoplasms*
  • Contraception
  • Contraceptives, Oral*
  • Disease
  • Family Planning Services
  • Injections*
  • Neoplasms
  • Risk Factors*


  • Contraceptives, Oral